

**EMMESSAR BIOTECH & NUTRITION LTD**

**UNAUDITED FINANCIAL RESULTS AS ON 30TH SEPTEMBER 2015**

(Rs. In Lakhs)

Particulars	Current Qtr Ended 30.09.2015 Unaudited	Preceding Qtr Ended 30.06.2015 Unaudited	Corresponding Qtr Ended 30.09.2014 Unaudited	Half Year Ended 30.09.2015 Unaudited	Corresponding Half Year Ended 30.09.2014 Unaudited	Previous Year Ended 31.03.2015 Audited	
<b>01) Sales / Income from Operations (Gross)</b>	21.81	113.86	41.79	135.67	67.65	228.12	
Less: Excise Duty	0.24	5.05	3.28	5.29	3.62	9.09	
<b>(a) Net Sales / Income from operations</b>	21.57	108.81	38.51	130.38	64.03	219.03	
(b) Other Income	-	-	-	-	-	-	
<b>Total Income</b>	<b>21.57</b>	<b>108.81</b>	<b>38.51</b>	<b>130.38</b>	<b>64.03</b>	<b>219.03</b>	
<b>02) Expenditure</b>							
(a) (Increase) / Decrease in stock in trade	(3.55)	(13.04)	(26.30)	(16.59)	(38.55)	(26.95)	
(b) Consumption of Raw materials	8.09	43.16	26.96	51.25	44.59	102.27	
(c) Purchase of Traded goods	-	5.48	-	5.48	-	-	
(d) Employee Cost	7.58	7.69	5.99	15.27	11.95	28.42	
(e) Depreciation	0.37	0.37	1.71	0.74	3.42	6.87	
(f) Other Expenditure	12.13	51.11	38.96	63.24	60.88	129.88	
<b>Total Expenditure (a to f)</b>	<b>24.62</b>	<b>94.77</b>	<b>47.32</b>	<b>119.39</b>	<b>82.29</b>	<b>240.49</b>	
<b>03) Profit from Operations before Other Income Interest &amp; Exceptional items (1 - 2)</b>	(3.05)	14.04	(8.81)	10.99	(18.26)	(21.46)	
<b>04) Other Income</b>	0.33	10.02	1.66	10.35	4.58	5.73	
<b>05) Profit before Interest and Exceptional Items (3 + 4)</b>	(2.72)	24.06	(7.15)	21.34	(13.68)	(15.73)	
<b>06) Interest</b>	-	-	-	-	-	-	
<b>07) Profit after Interest but before Exceptional Items (5 - 6)</b>	(2.72)	24.06	(7.15)	21.34	(13.68)	(15.73)	
<b>08) Exceptional Items</b>	-	-	-	-	-	-	
<b>09) Profit / (-) Loss from Ordinary Activities Before Taxation (7 + 8)</b>	(2.72)	24.06	(7.15)	21.34	(13.68)	(15.73)	
<b>10) Tax Expense (Deferred tax)</b>	-	-	-	-	-	(3.94)	
<b>11) Net Profit / (Loss) from Ordinary Activities after Taxation (9 - 10)</b>	(2.72)	24.06	(7.15)	21.34	(13.68)	(11.79)	
<b>12) Extraordinary Item (net of tax expense)</b>	(2.82)	95.00	-	92.18	-	-	
<b>13) Net Profit / Loss for the period (11-12)</b>	0.10	(70.94)	(7.15)	(70.84)	(13.68)	(11.79)	
<b>14) Paid-up Equity Share Capital (Face Value of the share)</b>	499.61	499.61	499.61	499.61	499.61	499.61	
	10.00	10.00	10.00	10.00	10.00	10.00	
<b>15) Reserves excluding Revaluation Reserve as per Balance Sheet of previous accounting year</b>	-	-	-	-	-	-	
<b>16) Earning per Shares</b>	0.00	(1.42)	(0.14)	(1.42)	(0.27)	(0.24)	
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annulled)							
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulled)							
<b>PART II</b>							
<b>A. PARTICULARS OF SHAREHOLDINGS</b>							
<b>1) Public Shareholding</b>							
- No. of Shares	2074356	2106676	2183781	2074356	2340026	2302713	
- Percentage of Shareholding	41.52	42.17	43.71	41.52	46.84	46.09	
<b>2) Promoters &amp; Promoters Group Shareholding</b>							
<b>a) Pledged / Encumbered</b>							
- No. of Shares	Nil	Nil	Nil	Nil	Nil	Nil	
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil	Nil	Nil	
- Percentage of Shares (as % of the total Share Capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil	
<b>b) Non Encumbered</b>							
- No. of Shares	2921744	2889424	2812319	2921744	2656074	2693387	
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	100%	100%	100%	100%	100%	100%	
- Percentage of Shares (as % of the total Share Capital of the Company)	58.48	57.83	56.29	58.48	53.16	53.91	
<b>Three Months ended: 30.09.2015</b>							
<b>B. INVESTORS COMPLAINTS</b>							
Pending at the beginning of the quarter					Nil		
Received during the quarter					Nil		
Disposed of during the quarter					Nil		
Remaining unresolved at the end of the quarter.					Nil		
* The above results were reviewed by the Audit Committee of the Board of Directors.							
* The Statutory Auditors have carried out a Limited Review of the results for the quarter ended September 30, 2015.							
* The above Un-Audited Results were taken on record at the meeting of the Board of Directors held on 6th November, 2015.							
<b>Mumbai</b>						<b>By order of the Board</b>	
<b>6th November, 2015</b>						<b>MSR Ayyangar</b>	
						<b>Managing Director</b>	

**EMMESSAR BIOTECH & NUTRITION LIMITED**  
**REVISED FINANCIAL RESULTS**

Quarter ended Segment wise Revenue Results and Capital Employed						
[Rs. In Lakhs]						
Particulars	Current Qtr Ended 30.09.2015 Unaudited	Preceding Qtr Ended 30.06.2015 Unaudited	Corresponding Qtr Ended 30.09.2014 Unaudited	Half Year Ended 30.09.2015 Unaudited	Corresponding Half Year Ended 30.09.2014 Unaudited	Previous Year Ended 31.03.2015 Audited
<b>1. Segment Revenue (Net Sales / Income)</b>						
a. Healthcare	19.32	20.79	11.51	40.11	18.85	44.82
b. Fine Chemicals	2.25	88.02	27.00	90.27	45.18	174.20
c. Others	0.33	10.02	1.66	10.35	4.58	5.48
<b>Total:</b>	<b>21.90</b>	<b>118.83</b>	<b>40.17</b>	<b>140.73</b>	<b>68.61</b>	<b>224.50</b>
<b>Less: Inter Segment Revenue</b>	-	-	-	-	-	-
<b>Net Sales / Income from Operations</b>	<b>21.90</b>	<b>118.83</b>	<b>40.17</b>	<b>140.73</b>	<b>68.61</b>	<b>224.50</b>
<b>2. Segment Results (Profit / Loss) before Tax and Interest</b>						
a. Healthcare	14.84	12.48	5.60	27.32	9.58	26.30
b. Fine Chemicals	(0.37)	21.75	2.81	21.38	4.93	26.10
c. Others	0.33	10.02	1.66	10.35	4.58	5.48
<b>Total:</b>	<b>14.80</b>	<b>44.25</b>	<b>10.07</b>	<b>59.05</b>	<b>19.09</b>	<b>57.88</b>
<b>Less:</b>						
Interest	-	-	-	-	-	-
Other Unallocable Expenditure net off Unallocable Income	17.52	20.19	17.22	37.71	32.77	73.61
<b>Total Profit before Tax</b>	<b>(2.72)</b>	<b>24.06</b>	<b>(7.15)</b>	<b>21.34</b>	<b>(13.68)</b>	<b>(15.73)</b>
<b>3. Capital Employed (Segment Assets - Segment Liabilities)</b>						
a. Healthcare	19.51	4.91	16.49	19.51	16.49	13.41
b. Fine Chemicals	39.76	79.45	12.66	39.76	12.66	28.38
c. Others	(56.96)	(79.14)	(40.06)	(56.96)	(40.06)	(37.51)
<b>Total:</b>	<b>2.31</b>	<b>5.22</b>	<b>(10.91)</b>	<b>2.31</b>	<b>(10.91)</b>	<b>4.28</b>

**Note:** The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 6th November, 2015.

Mumbai  
6th November, 2015

By order of the Board  
MSR Ayyangar  
Managing Director

<b>EMMESSAR BIOTECH &amp; NUTRITION LTD</b>			
<b>Statements of Assets &amp; Liabilities</b>			
<b>(Rs. In Lakhs)</b>			
	<b>Particulars</b>	<b>As at 30.09.2015</b>	<b>As at 31.03.2015</b>
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>SHAREHOLDER'S FUNDS:</b>		
	(a) Share Capital	499.61	499.61
	(b) Reserves & Surplus	(433.01)	(362.17)
	<b>Sub-total Shareholder's funds</b>	<b>66.60</b>	<b>137.44</b>
<b>2</b>	<b>Non-current Liabilities</b>		
	(a) Long-term borrowings	9.97	4.79
	(b) Deferred tax liabilities (net)	10.04	10.04
	<b>Sub-total Non-current liabilities</b>	<b>20.01</b>	<b>14.83</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Trade payables	17.90	30.90
	(b) Other current Liabilities	73.34	54.40
	(c) Short-term provisions	0.86	4.37
	<b>Sub-total Current Liabilities</b>	<b>92.10</b>	<b>89.67</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>178.71</b>	<b>241.94</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Fixed Assets	73.75	142.47
	(b) Non-current investments	0.57	0.57
	(c) Long-term loans and advances	13.86	11.90
	<b>Sub-total Non-current Assets</b>	<b>88.18</b>	<b>154.94</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	73.18	68.77
	(b) Trade Receivables	4.25	3.93
	(c) Cash & Cash equivalents	2.77	2.40
	(d) Short-term loans and advances	10.33	11.90
	<b>Sub-total Current Assets</b>	<b>90.53</b>	<b>87.00</b>
	<b>TOTAL ASSETS</b>	<b>178.71</b>	<b>241.94</b>